poisar

Stock

agilon health, inc. AGL

$96.08+8.08%

Overview

AGL market data

Price History

AGL price chart

Valuation & Profitability

Provider-backed
P/E (TTM)
Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
Forward P/E
P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
EPS (TTM)
-$23.63
Diluted earnings per share over the trailing twelve months.
Beta
2.96
Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
Dividend Yield
Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
Profit Margin
-3.9%
Net income divided by revenue. Comparable within a sector, less so across sectors.
52w range
$7.48 – $133.04
Lowest and highest closing prices over the past 52 weeks.
Analyst Target
Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.

Display-only. Refreshed once per symbol per 24 hours · market cap $1.5B · P/B 2.25 · P/S 0.25.

Company News

10 captured
Wells Fargo Maintains Overweight on Agilon Health, Raises Price Target to $146Benzinga · Aug 11, 2026, 1:06 PM
This Best Buy Analyst Turns Bullish; Here Are Top 5 Upgrades For TuesdayBenzinga · Aug 11, 2026, 12:27 PM
Citigroup Upgrades Agilon Health to Neutral, Raises Price Target to $115Benzinga · Aug 11, 2026, 12:22 PM
Truist Securities Maintains Hold on Agilon Health, Raises Price Target to $112Benzinga · Aug 6, 2026, 4:12 PM
Benchmark Maintains Buy on Agilon Health, Raises Price Target to $140Benzinga · Aug 6, 2026, 3:40 PM
Evercore ISI Group Maintains In-Line on Agilon Health, Raises Price Target to $125Benzinga · Aug 6, 2026, 2:37 PM
Barclays Maintains Equal-Weight on Agilon Health, Raises Price Target to $111Benzinga · Aug 6, 2026, 12:25 PM
CORRECTION: Agilon Health Sees Q3 Sales $1.445B-$1.475B vs $1.415B EstBenzinga · Aug 5, 2026, 10:12 PM
CORRECTION: Agilon Health Raises FY2026 Sales Guidance from $5.680B-$5.805B to $5.775B-$5.860B vs $5.719B EstBenzinga · Aug 5, 2026, 10:10 PM
Agilon Health Lowers FY2026 Sales Guidance from $5.680B-$5.805B to $1.445B-$1.475B vs $5.719B EstBenzinga · Aug 5, 2026, 8:37 PM

Decision & Score

Members

Our Tradable / Watch / Avoid decision and 0–100 conviction score for this symbol are members-only.

Create account to unlock

Trend & Pattern Evidence

Members

Trend alignment and backtested chart-pattern probabilities are members-only.

Create account to unlock

Sector Peer Ranking

Members

Ranked sector peers with scores and decisions are members-only.

Create account to unlock